Effects of bisoprolol combined with rosuvastatin on endothelial function and inflammation in patients with coronary slow flow
10.11958/20150413
- VernacularTitle:比索洛尔联合瑞舒伐他汀对冠状动脉慢血流患者内皮功能及炎症的影响
- Author:
Min HUANG
;
Zhonghua XIA
;
Fusheng XIE
;
Tiantian ZHOU
- Publication Type:Journal Article
- Keywords:
coronary slow flow;
bisoprolol;
rosuvastatin;
endothelium,vascular;
inflammation;
nitric oxide;
endothelin-1;
hypersensitive C-reactive protein;
interleukin-6
- From:
Tianjin Medical Journal
2016;44(9):1139-1142,1143
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effects of bisoprolol combined with rosuvastatin on endothelial function and inflammation in patients with coronary slow flow (CSF). Methods Ninety CSF patients treated from August 2014 to October 2015 were randomly divided into control group, statin group and combined group, thirty cases in each group. The control group was given conventional therapy (aspirin 100 mg/d and isosorbide mononitrate 60 mg/d), statin group was given rosuvastatin 10 mg/d on the basic of control group, while the combined group was given bisoprolol 5 mg/d on the basic therapy of statin group. The serum concentrations of nitric oxide (NO), endothelin-1(ET-1), high-sensitivity c-reactive protein (hs-CRP) and interleukin-6 (IL-6) were detected before treatment and 8 weeks after treatment. The improvement of patients with angina pectoris was evaluated. Results After eight-week treatment, the NO levels were significantly increased in combined group and statin group, while the ET-1, hs-CRP and IL-6 levels were significantly decreased than those before the treatment (P<0.05). At the same time, comparing with the statin group and control group, the NO level was increased in combined group (P<0.05), while the ET-1, hs-CRP, and IL-6 levels decreased significantly (P<0.05). There were significant differences in the effective rates between the combined group (90.0%) and the statin group (83.3%), which were higher than those in control group (56.7%). Conclusion Bisoprolol combined with rosuvastatin can improve the endothelial function and anti-inflammatory in the treatment of CSF.
